Oct. 22 at 4:13 PM
Shares of Nurix Therapeutics Inc. rose on Wednesday after the company announced the launch of its pivotal DAYBreak clinical trial — a single-arm Phase 2 study of bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
The clinical-stage biopharmaceutical company, focused on targeted protein degradation therapies, will evaluate a 600 mg once-daily dose in the DAYBreak study. This dosage was selected following analysis from a randomized cohort in the Phase 1b trial, in alignment with global regulators including the FDA, the UK’s MHRA, and the EMA.
“The initiation of the DAYBreak study marks Nurix’s transition to a pivotal-stage company and represents an important milestone for bexobrutideg, which our data suggest has a potentially best-in-class profile,” said Arthur T. Sands, M.D., Ph.D., president and CEO of Nurix.
The DAYBreak trial will enroll CLL patients whose disease has progressed after multiple prior treatments.
$NRIX